Alamar Biosciences Reports 99% Revenue Growth and Secures $197.8M Net Proceeds from IPO
ALMR is trading near its 52-week low of $21.75 (11% above the low).
Summary
Alamar Biosciences reported a 99% increase in Q1 2026 revenue to $26.0 million and an improved gross margin of 56%, alongside the successful completion of its IPO in April, which generated $197.8 million in net proceeds.
Key Events · Earnings and Guidance · ALMR
-
Exceptional Revenue Growth
Total revenue for the first quarter of 2026 reached $26.0 million, marking a significant 99% increase compared to $13.1 million in the corresponding period of 2025. Consumable revenue notably grew by 178%.
-
Improved Gross Margin
Gross margin expanded to 56% for Q1 2026, up from 49% in the prior-year period, driven by manufacturing efficiencies and a favorable shift in product mix.
-
Successful Initial Public Offering (IPO)
In April 2026, after the quarter end, Alamar Biosciences completed its IPO, raising $197.8 million in net proceeds. This significantly strengthens the company's balance sheet and provides substantial capital for future growth.
-
Increased Net Loss
The company reported a net loss of $21.3 million for Q1 2026, compared to $7.7 million in Q1 2025. This includes an $8.6 million loss related to the remeasurement of convertible notes.
Analysis · ALMR · Industrial Applications And Services
Alamar Biosciences delivered exceptional Q1 2026 financial results, nearly doubling revenue year-over-year and significantly expanding gross margins. This strong operational performance is further bolstered by the successful completion of its initial public offering in April, which raised substantial net proceeds of $197.8 million. This capital infusion provides a robust balance sheet, enabling the company to accelerate the adoption of its Precision Proteomics platform and fund future growth initiatives. While net loss increased, it was partly due to a non-cash convertible note remeasurement, and the overall financial position is significantly strengthened, de-risking the company's near-term funding needs.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALMR was trading at $24.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $21.75 to $27.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.